Skip to content

ADMA Biologics ADMA Balance Sheet Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$138.15M+57.7%$87.63M+42.8%$61.39M-32.0%$90.29M+26.1%$71.63M-30.6%
$135.86M-14.2%$158.43M+15.1%$137.67M+25.5%$109.73M+10.4%$99.41M+98.8%
$222.1M+7.6%$206.47M+5.0%$196.67M+2.7%$191.46M+11.2%$172.19M+1.1%
$511.17M+9.6%$466.51M+15.9%$402.66M+0.8%$399.56M+13.6%$351.81M+6.2%
$65.01M-0.1%$65.06M-6.4%$69.51M+20.9%$57.5M-0.4%$57.71M+5.5%
$3.53M0.0%$3.53M0.0%$3.53M0.0%$3.53M0.0%$3.53M0.0%
$630K-0.3%$632K+28.7%$491K-6.8%$527K+16.6%$452K-1.7%
$665.18M+6.6%$624.24M+9.8%$568.69M+1.8%$558.38M+9.4%$510.57M+4.5%
$20.52M-8.9%$22.52M-6.3%$24.02M-19.3%$29.77M+44.5%$20.61M+1.9%
$1.37M-2.6%$1.41M-2.4%$1.44M+907%$143K0.0%$143K0.0%
$3.28M+16.6%$2.81M+20.0%$2.34M
$73.54M+5.8%$69.54M+23.1%$56.49M-24.6%$74.94M+40.1%$53.5M-3.7%
$193.58M+179%$69.33M-1.1%$70.08M
$274.86M+87.1%$146.92M+6.9%$137.5M-14.1%$160.06M+16.7%$137.15M-1.8%
300M0.0%300M0.0%300M0.0%300M0.0%300M0.0%
-$116.33M+28.0%-$161.65M+23.4%-$211.03M+14.7%-$247.46M+12.1%-$281.68M+8.7%
$390.33M-18.2%$477.32M+10.7%$431.19M+8.2%$398.33M+6.7%$373.42M+7.0%
$665.18M+6.6%$624.24M+9.8%$568.69M+1.8%$558.38M+9.4%$510.57M+4.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ADMA Biologics's total assets?
ADMA Biologics (ADMA) holds $665.2M in total assets, up 30.3% year over year.
How much debt does ADMA Biologics have?
ADMA Biologics carries $204.4M in total debt against $390.3M of shareholders' equity, a debt-to-equity ratio of 0.52.
How much cash does ADMA Biologics have?
ADMA Biologics holds $138.2M in cash and equivalents.
Can ADMA Biologics cover its short-term obligations?
Its current ratio is 6.95 — current assets exceed current liabilities.
Where does ADMA Biologics's balance sheet data come from?
Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.